BUZZ - Bipolar disorder mania drug successful in mid-stage trial, Rapport shares surge

October 20 - ** Rapport Therapeutics (RAPP.O) shares rose 54.7% in pre-market trading to $44

** The company said its drug RAP-219 for the treatment of manic episodes in bipolar disorder met both primary and secondary endpoints in a mid-stage clinical trial

** Mania is a distinct period lasting at least a week, characterized by abnormally elevated, irritable, or euphoric mood accompanied by a sharp increase in energy, activity levels, and racing thoughts

** Rapport said that patients receiving the treatment had an average decrease of 15.4 points on the Young Mania Rating Scale (YMRS), which is used to measure and quantify the severity of manic symptoms

** The company said that compared to placebo, all 11 indicators measured by YMRS at week 3 showed improvement, where irritability and destructive aggressive behavior achieved nominal significance

** As of the close of the previous trading day, the stock had fallen 5.7% year to date

(For the convenience of non-English speakers, Reuters provides automated translations of its reports into several other languages. Because automated translation may contain errors or may not include the required context, Reuters does not guarantee the accuracy of the translated text and provides it solely for reader convenience. Reuters assumes no responsibility for any harm or loss arising from the use of the automated translation feature.)